Login
$GRVE
$0.00 +$0.00 (0.0%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2027
As of Jun 30, 2026
Q4 FY2026
As of Mar 31, 2026
Q3 FY2026
As of Dec 31, 2025
Q2 FY2026
As of Sep 30, 2025
Q1 FY2026
As of Jun 30, 2025
Q4 FY2025
As of Mar 31, 2025
Q3 FY2025
As of Dec 31, 2024
Q2 FY2025
As of Sep 30, 2024
Q1 FY2025
As of Jun 30, 2024
Q4 FY2024
As of Mar 31, 2024
Q3 FY2024
As of Dec 31, 2023
Q2 FY2024
As of Sep 30, 2023
Q1 FY2018
As of Jun 30, 2017
Q3 FY2018
As of Dec 31, 2017
Q2 FY2018
As of Sep 30, 2017
Q2 FY2017
As of Sep 30, 2016
Q4 FY2017
As of Mar 31, 2017
Q3 FY2017
As of Dec 31, 2016
Q1 FY2017
As of Jun 30, 2016
Q4 FY2016
As of Mar 31, 2016
Accounts Receivable
Cash
Prepaid Expenses
Total Current Assets
TOTAL ASSETS
Accounts Payable and Accrued Liabilities
Interest Payable
Convertible Notes Payable
Related Party Payable
Series A Preferred Stock
Total related Party Payable
Dividends
Series A Preferred Stock
Series B Preferred Stock
Total dividends
Dividends payable, related party
Total Current Liabilities
Total Liabilities
Common Stock, $0.001 par value, 200,000,000 shares authorized. and 59,643,062 shares issued and outstanding as of June 30, 2026, and March 31, 2026
Preferred Stock, Value
Series A Preferred Stocks
Series B Preferred Stocks
Series A Preferred Stock
Series B Preferred Stock
Additional paid-in capital
Accumulated deficit
Total stockholders' deficit
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support